Product Description
Elotuzumab injection is used together with lenalidomide and dexamethasone to treat multiple myeloma (a blood cell cancer) in patients who have received one to three previous cancer treatments. It is also used together with pomalidomide and dexamethasone to treat multiple myeloma in patients who have received at least two previous cancer treatments (eg, lenalidomide, proteasome inhibitor). Elotuzumab interferes with the growth of cancer cells, which are then destroyed by the body. It is an antineoplastic agent (cancer medicine). (Sourced from: https://www.mayoclinic.org/drugs-supplements/elotuzumab-intravenous-route/description/drg-20168748)
Mechanisms of Action: SLAMF7 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Poland | Portugal | Russia | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, Finland, Greece, Hungary, Italy, Japan, Poland, Romania, Spain, Sweden, Turkey, United Kingdom, United States
Active Clinical Trial Count: 14
Highest Development Phases
Phase 3: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT06518551 | P2 |
Recruiting |
Multiple Myeloma |
2029-12-31 |
|
| 2017-001616-11 | P3 |
Active, not recruiting |
Multiple Myeloma |
2027-06-25 |
|
| CC-220 | P1 |
Active, not recruiting |
Multiple Myeloma |
2025-11-01 |
|
| IRB16-1138 | P2 |
Active, not recruiting |
Multiple Myeloma |
2025-03-01 |